- Home
- OPAD vs NRXP Comparison
OPAD vs NRXP Comparison
Compare OPAD & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPAD
- NRXP
- Stock Information
- Founded
- OPAD 2015
- NRXP 2015
- Country
- OPAD United States
- NRXP United States
- Employees
- OPAD N/A
- NRXP N/A
- Industry
- OPAD Real Estate
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- OPAD Finance
- NRXP Health Care
- Exchange
- OPAD Nasdaq
- NRXP Nasdaq
- Market Cap
- OPAD 25.3M
- NRXP 58.5M
- IPO Year
- OPAD N/A
- NRXP N/A
- Fundamental
- Price
- OPAD $1.41
- NRXP $2.84
- Analyst Decision
- OPAD Hold
- NRXP Strong Buy
- Analyst Count
- OPAD 5
- NRXP 4
- Target Price
- OPAD $2.38
- NRXP $28.50
- AVG Volume (30 Days)
- OPAD 2.2M
- NRXP 137.7K
- Earning Date
- OPAD 08-04-2025
- NRXP 08-13-2025
- Dividend Yield
- OPAD N/A
- NRXP N/A
- EPS Growth
- OPAD N/A
- NRXP N/A
- EPS
- OPAD N/A
- NRXP N/A
- Revenue
- OPAD $794,159,000.00
- NRXP N/A
- Revenue This Year
- OPAD N/A
- NRXP N/A
- Revenue Next Year
- OPAD $40.79
- NRXP $230.95
- P/E Ratio
- OPAD N/A
- NRXP N/A
- Revenue Growth
- OPAD N/A
- NRXP N/A
- 52 Week Low
- OPAD $0.91
- NRXP $1.10
- 52 Week High
- OPAD $5.13
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- OPAD 44.75
- NRXP 38.54
- Support Level
- OPAD $1.35
- NRXP $2.89
- Resistance Level
- OPAD $4.95
- NRXP $3.15
- Average True Range (ATR)
- OPAD 0.71
- NRXP 0.14
- MACD
- OPAD -0.10
- NRXP -0.04
- Stochastic Oscillator
- OPAD 2.20
- NRXP 10.22
About OPAD Offerpad Solutions Inc.
Offerpad Solutions Inc provides a way to buy and sell a home. It uses technology-enabled solutions to remake the home selling and buying experience by offering customers the convenience, control, and certainty to solve their housing needs. It combines fundamental real estate expertise with the data-driven digital Solutions Center platform to efficiently sell and buy their homes online with streamlined access to other services including mortgage, listing, renovation and buyer representation services.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.